Quest Diagnostics SVP acquires 33 shares

The shares qualified for deferred Form 5 reporting under Rule 16a-6, but Kuppusamy chose to report the transaction early.

Rhea-AI Filing Summary

Quest Diagnostics SVP, Clinical Solutions Karthik Kuppusamy acquired 33 common shares at $235.9440 per share on October 21, 2026, through a dividend reinvestment plan administered by his broker. His reported direct holdings after the transaction were 13,619 shares, including exempt purchases under the company’s stock purchase plan since his prior Form 4. The report also lists 358 shares held by a trust and 1,697 shares associated with the company’s 401(k) plan; the latter figure is based on the plan’s stock-fund account balance, which includes some money-market instruments.

Insider Trade Summary

Small Acquisition: 33 shares

Small Acquisition 3 txns

Insider KUPPUSAMY KARTHIK

Role SVP, Clinical Solutions

Type	Security	Shares	Price	Value
Small Acquisition	Common Stock F1, F2	33	$235.944	$8K
holding	Common Stock	--	--	--
holding	Common Stock F3	--	--	--

Holdings After Transaction: Common Stock — 13,619 shares (Direct); Common Stock — 358 shares (Indirect, By Trust); Common Stock — 1,697 shares (Indirect, 401(k))

Footnotes (3)

1. F1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
2. F2. The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4.
3. F3. These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under the Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.

Key Figures

Common shares acquired: 33 shares Price per share: $235.9440 per share Direct shares following transaction: 13,619 shares +2 more

5 metrics

Common shares acquired 33 shares Dividend reinvestment plan acquisition on October 21, 2026

Price per share $235.9440 per share Dividend reinvestment plan acquisition on October 21, 2026

Direct shares following transaction 13,619 shares Includes exempt purchases under the company’s stock purchase plan since the prior Form 4

Shares held by trust 358 shares Indirect holding reported on October 21, 2026

401(k) plan shares 1,697 shares Reported holding based on the company stock-fund account balance

Key Terms

dividend reinvestment plan, deferred reporting, Rule 16a-6, tax qualified Profit Sharing (401(k)) Plan

4 terms

dividend reinvestment plan financial

"acquired pursuant to a dividend reinvestment plan"

A dividend reinvestment plan lets shareholders automatically use cash dividends to buy more shares of the same company instead of receiving the money. It matters to investors because it turns regular payouts into a steady way to grow ownership and take advantage of compound returns—like having your savings automatically buy additional slices of a pie over time—while often reducing transaction costs and smoothing purchase timing.

deferred reporting regulatory

"eligible for deferred reporting on Form 5"

Rule 16a-6 regulatory

"under Rule 16a-6"

tax qualified Profit Sharing (401(k)) Plan technical

"Company's tax qualified Profit Sharing (401(k)) Plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many DGX shares did Karthik Kuppusamy acquire, and at what price?

Karthik Kuppusamy acquired 33 Quest Diagnostics common shares at $235.9440 per share on October 21, 2026, through a dividend reinvestment plan administered by his broker.

Why did Karthik Kuppusamy report the DGX share acquisition early?

The shares were eligible for deferred reporting on Form 5 under Rule 16a-6, and Kuppusamy chose to report the transaction early on Form 4.

What DGX shares were listed through Karthik Kuppusamy’s trust and 401(k)?

The report lists 358 shares held by a trust and 1,697 shares associated with the company’s 401(k) plan. The 401(k) figure is based on the account balance of the company stock fund, which includes some money-market instruments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/23/2026 - 07:32 PM EDT Accepted by SEC EDGAR 10/23/2026 - 07:32 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KUPPUSAMY KARTHIK

(Last) (First) (Middle)

500 PLAZA DRIVE

C/O QUEST DIAGNOSTICS INC

(Street)

SECAUCUS NEW JERSEY 07094

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Clinical Solutions

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/21/2026		L	V	33(1)	A	$235.944	13,619(2)	D
Common Stock								358	I	By Trust
Common Stock								1,697(3)	I	401(k)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

2. The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4.

3. These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under the Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.

Remarks:

	Sean D. Mersten, Attorney in Fact for Karthik Kuppusamy	10/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)